Fort Washington Investment Advisors Inc. OH Has $42.64 Million Stake in Pfizer Inc. (NYSE:PFE)

Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,682,821 shares of the biopharmaceutical company's stock after purchasing an additional 53,433 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Pfizer were worth $42,643,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Mcdonald Partners LLC increased its holdings in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after purchasing an additional 9,963 shares during the period. Bank of Jackson Hole Trust acquired a new position in shares of Pfizer during the fourth quarter valued at $264,000. Harvey Capital Management Inc. acquired a new position in shares of Pfizer during the fourth quarter valued at $544,000. ING Groep NV increased its holdings in shares of Pfizer by 48.6% during the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock valued at $26,881,000 after purchasing an additional 331,403 shares during the period. Finally, Strategic Financial Concepts LLC acquired a new position in Pfizer during the fourth quarter worth about $2,281,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Trading Up 1.5%

Shares of NYSE:PFE traded up $0.37 during midday trading on Thursday, reaching $24.85. The company had a trading volume of 42,445,910 shares, compared to its average volume of 41,112,573. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a market cap of $141.28 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a fifty day simple moving average of $22.96 and a two-hundred day simple moving average of $24.98.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company posted $0.82 EPS. The business's quarterly revenue was down 7.8% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 6.92%. Pfizer's payout ratio is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.